A Phase 2 interventional study of BCD-131 and Mircera in Anemia, sponsored by Biocad. Completed at 3 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-03-04.
Sponsored by Biocad · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Anemia with a site in Russian Federation — 1 open to participants now, 2 under way, 1 of them phase 3. Anemia · Russian Federation.
Among the 54 studies in Anemia with a site in Russian Federation, this one is the 43rd largest by enrollment of the 51 interventional ones that give a count, is one of 4 that started in 2017, is one of 12 in phase 2, and was the 48th registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →1 of the 54 studies in Anemia with a site in Russian Federation is open now. Recruiting first, the newest first:
Russian Federation of Anesthesiologists and Reanimatologists · Sites in Russian Federation
Ages 18+
A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 13 · Phase 3 36 · Phase 4 3
First in 2000; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 75 is below the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 311 across the 51 interventional studies, 3,554 across the 3 observational. Of the 51 that completed or were terminated, 40 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 54 have an industry lead sponsor. The 10 most frequent:
Biocad is the lead sponsor of 94 studies on the registry; 12 are open to participants now.
Biocad has 3 studies filed under Anemia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 54 studies in Anemia with a site in Russian Federation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
BCD-131 is pegylated darbepoetin beta. BCD-131-2 is International Multicenter Randomized Open-Label Comparative Study (Phase II) of the Efficacy and Safety of BCD-131 and Mircera in Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis.
The hypothesis of the study is that the efficacy of BCD-131 is equivalent to that of Mircera® based on the analysis of the primary endpoint (changes in the Hb level over the period of evaluation as compared to the baseline Hb level ) during the 21-week period of treatment.
This study is a study of the maintenance treatment of anemia. The study will include up to 100 dialysis patients with stage 5D chronic kidney disease, established efficacy of dialysis and renal anemia without other causes of anemia, receiving erythropoiesis-stimulating agents (ESA) and reaching target hemoglobin levels.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
subcutaneously monthly
Biological: BCD-131
subcutaneously monthly
Biological: BCD-131
Subcutaneously monthly
Biological: BCD-131
subcutaneously monthly
Biological: Mircera
subcutaneously monthly
Also known as: pegylated darbepoetin beta
subcutaneously monthly
Also known as: Methoxy polyethylene glycol-epoetin beta
Change in Hemoglobin (Hb) Concentration From Baseline to the Evaluation Period
The baseline hemoglobin will be calculated as the arithmetic mean of hemoglobin values obtained at screening and at Visit 1. The final hemoglobin value during the evaluation period will be calculated as the arithmetic mean of hemoglobin values obtained at Week 21 and Week 23.
Time frame: Baseline - measurements on Screening (weeks -4 - 0) and on day 1; Evaluation period - weekly measures on weeks 21 to 23
The Proportion of Patients Who Developed AEs/SAEs That, in the Investigator's Opinion, Are Related to BCD-131
The proportion of patients, in each group, who developed СТСАЕ v. 4.03 Grade 3-4 AEs that, in the Investigator's opinion, are related to BCD-131 - the proportion of patients, in each group, who discontinued the study due to AEs/SAEs
Time frame: Week 23
The Proportion of BAb- and NAb-positive Patients
Blood sampling for immunogenicity assessment (BAbs and NAbs) will be performed in all the patients included in the study before the first injection and then at Week 9 and Week 23. The immunogenicity endpoints will be analyzed after the completion of all periods of the study.
Time frame: Week 9, 23
AUC(0-672 Hour)
Area under the concentration curve from the moment of injection to 672 h \[28 days\])
Time frame: 3, 6, 12, 24, 48, 72, 96, 168, 336, 504, 672 h h after injection 1
AUC(0-∞)
Area under the concentration curve from the moment of injection to infinity
Time frame: 3, 6, 12, 24, 48, 72, 96, 168, 336, 504, 672 h h after injection 1, weeks 5, 9, 13, 17, 21
Cmax
Maximum serum concentration of the drug product) after the first injection of the test/reference drug
Time frame: 3, 6, 12, 24, 48, 72, 96, 168, 336, 504, 672 h h after injection 1, weeks 5, 9, 13, 17, 21
AUEC(0-672 Hour)
Area under the effect curve from the drug injection to 672 h \[28 days\]) based on the change in the absolute reticulocyte count after the first injection of the test/reference drug
Time frame: 3, 6, 12, 24, 48, 72, 96, 168, 336, 504, 672 h h after injection 1
AC-Emax
Maximum absolute reticulocyte count after the first injection of BCD-131/Mircera®
Time frame: day 28
| Milestone | BCD-131 1,05 mcg/kg * Conversion Ratio | BCD-131 1,7 mcg/kg * Conversion Ratio | BCD-131 2,75 mcg/kg * Conversion Ratio | Mircera |
|---|---|---|---|---|
| Started | 25 | 25 | 0 | 25 |
| Completed | 20 | 21 | 0 | 24 |
| Not completed | 5 | 4 | 0 | 1 |
The baseline hemoglobin will be calculated as the arithmetic mean of hemoglobin values obtained at screening and at Visit 1. The final hemoglobin value during the evaluation period will be calculated as the arithmetic mean of hemoglobin values obtained at Week 21 and Week 23.
| g/L | BCD-131 1,05 mcg/kg * Conversion Ratio | BCD-131 1,7 mcg/kg * Conversion Ratio | Mircera |
|---|---|---|---|
| Change in Hemoglobin (Hb) Concentration From Baseline to the Evaluation Period | -3.25 (-12 to 0.5) | 3.5 (-7 to 14) | -2.75 (-9.5 to 9) |
The proportion of patients, in each group, who developed СТСАЕ v. 4.03 Grade 3-4 AEs that, in the Investigator's opinion, are related to BCD-131 - the proportion of patients, in each group, who discontinued the study due to AEs/SAEs
| Participants | BCD-131 1,05 mcg/kg * Conversion Ratio | BCD-131 1,7 mcg/kg * Conversion Ratio | Mircera |
|---|---|---|---|
| The Proportion of Patients Who Developed AEs/SAEs That, in the Investigator's Opinion, Are Related to BCD-131 | 5 | 2 | 2 |
Blood sampling for immunogenicity assessment (BAbs and NAbs) will be performed in all the patients included in the study before the first injection and then at Week 9 and Week 23. The immunogenicity endpoints will be analyzed after the completion of all periods of the study.
| Participants | BCD-131 1,05 mcg/kg * Conversion Ratio | BCD-131 1,7 mcg/kg * Conversion Ratio | Mircera |
|---|---|---|---|
| The Proportion of BAb- and NAb-positive Patients | 0 | 0 | 0 |
Area under the concentration curve from the moment of injection to 672 h \[28 days\])
| (mmol/L)*h | BCD-131 1,05 mcg/kg * Conversion Ratio | BCD-131 1,7 mcg/kg * Conversion Ratio | Mircera |
|---|---|---|---|
| AUC(0-672 Hour) | 51744.45 (31201.8 to 87463.5) | 73948.8 (57057.15 to 133730.25) | 89409.3 (35389.95 to 166699.5) |
Area under the concentration curve from the moment of injection to infinity
| (mmol/L)*h | BCD-131 1,05 mcg/kg * Conversion Ratio | BCD-131 1,7 mcg/kg * Conversion Ratio | Mircera |
|---|---|---|---|
| AUC(0-∞) | 65150.045 (43463.791 to 91305.66) | 81698.001 (63442.206 to 142665.693) | 96259.513 (46985.695 to 192570.672) |
Maximum serum concentration of the drug product) after the first injection of the test/reference drug
| mmol/L | BCD-131 1,05 mcg/kg * Conversion Ratio | BCD-131 1,7 mcg/kg * Conversion Ratio | Mircera |
|---|---|---|---|
| Cmax | 195.3 (148.7 to 407.1) | 231.9 (187.2 to 488.2) | 617.6 (130.6 to 943.2) |
Area under the effect curve from the drug injection to 672 h \[28 days\]) based on the change in the absolute reticulocyte count after the first injection of the test/reference drug
| (cells*10^9)*h | BCD-131 1,05 mcg/kg * Conversion Ratio | BCD-131 1,7 mcg/kg * Conversion Ratio | Mircera |
|---|---|---|---|
| AUEC(0-672 Hour) | 7210.479 ± 5465.155 | 11274.380 ± 12460.177 | 12131.820 ± 15613.087 |
Maximum absolute reticulocyte count after the first injection of BCD-131/Mircera®
| (cells*10^9)/L | BCD-131 1,05 mcg/kg * Conversion Ratio | BCD-131 1,7 mcg/kg * Conversion Ratio | Mircera |
|---|---|---|---|
| AC-Emax | 96.650 ± 29.185 | 107.047 ± 38.615 | 154.753 ± 58.729 |
Collected over 25 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BCD-131 1,05 mcg/kg * Conversion Ratio | 1/25 (4%) | 6/25 (24%) | 13/25 (52%) |
| BCD-131 1,7 mcg/kg * Conversion Ratio | 2/25 (8%) | 4/25 (16%) | 16/25 (64%) |
| Mircera | 0/25 (0%) | 3/25 (12%) | 15/25 (60%) |
| Event | BCD-131 1,05 mcg/kg * Conversion Ratio | BCD-131 1,7 mcg/kg * Conversion Ratio | Mircera |
|---|---|---|---|
| subcutaneous tissueSkin and subcutaneous tissue disorders | 1/25 | 0/25 | 0/25 |
| consequence of strokeNervous system disorders | 1/25 | 0/25 | 0/25 |
| fracture of the left ankleMusculoskeletal and connective tissue disorders | 1/25 | 0/25 | 0/25 |
| Hemorrhagic strokeNervous system disorders | 1/25 | 0/25 | 0/25 |
| Ischemic Heart DiseaseCardiac disorders | 1/25 | 0/25 | 0/25 |
| non-Q wave myocardial infarctionCardiac disorders | 1/25 | 0/25 | 0/25 |
| Arteriovenous Access ThrombosisVascular disorders | 0/25 | 1/25 | 1/25 |
| myocardial infarctionCardiac disorders | 0/25 | 1/25 | 0/25 |
| Type 2 diabetes. Diabetic foot syndromeEndocrine disorders | 0/25 | 1/25 | 0/25 |
| Catheter-associated infectionInfections and infestations | 0/25 | 1/25 | 0/25 |
| Event | BCD-131 1,05 mcg/kg * Conversion Ratio | BCD-131 1,7 mcg/kg * Conversion Ratio | Mircera |
|---|---|---|---|
| hyperglycemiaInvestigations | 6/25 | 4/25 | 2/25 |
| systolic blood pressure increase (isolated)Vascular disorders | 3/25 | 6/25 | 4/25 |
| dyastolic blood pressure increase (isolated)Vascular disorders | 2/25 | 4/25 | 6/25 |
| arterial pressure increaseVascular disorders | 4/25 | 3/25 | 3/25 |
| lymphocytes decreaseInvestigations | 4/25 | 2/25 | 1/25 |
| leukocytes decreaseInvestigations | 2/25 | 1/25 | 1/25 |
| neutrophils decreaseInvestigations | 2/25 | 2/25 | 2/25 |
| ECG changesCardiac disorders | 0/25 | 2/25 | 2/25 |
| lymphocytes increaseInvestigations | 1/25 | 0/25 | 2/25 |
| Age, Continuous(years) | BCD-131 1,05 mcg/kg * Conversion Ratio | BCD-131 1,7 mcg/kg * Conversion Ratio | Mircera | Total |
|---|---|---|---|---|
| Median | 60 (48 to 64) | 54 (46 to 63) | 47 (35 to 58) | 55 (46 to 63) |
| Sex: Female, Male(Participants) | BCD-131 1,05 mcg/kg * Conversion Ratio | BCD-131 1,7 mcg/kg * Conversion Ratio | Mircera | Total |
|---|---|---|---|---|
| Female | 14 | 12 | 11 | 37 |
| Male | 11 | 13 | 14 | 38 |
| Race (NIH/OMB)(Participants) | BCD-131 1,05 mcg/kg * Conversion Ratio | BCD-131 1,7 mcg/kg * Conversion Ratio | Mircera | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 24 | 25 | 24 | 73 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 | 2 |
| Region of Enrollment(participants) | BCD-131 1,05 mcg/kg * Conversion Ratio | BCD-131 1,7 mcg/kg * Conversion Ratio | Mircera | Total |
|---|---|---|---|---|
| Belarus | 5 | 1 | 2 | 8 |
| Russia | 20 | 24 | 23 | 67 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2017 to primary completion in Dec 2018, 13 months.
Results were first posted in Jul 2019, 7 months after primary completion.
Of 58 industry-sponsored phase 2 interventional studies under Anemia, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 40. This study's 13 months is below that.
Counting every sponsor, half of 88 studies reached it within 28 months; a quarter within 16 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.